iRhythm Technologies, Inc. (IRTC)

74,83 +2,42 (+3,34%) Al cierre: 04:00PM EDT

iRhythm Technologies, Inc.

699 8th Street
Suite 600
San Francisco, CA 94103
United States
415 632 5700
https://www.irhythmtech.com

Sector(es): Healthcare
Sector: Medical Devices
Empleados a tiempo completo: 2000

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Quentin S. Blackford	President, CEO & Director	1,42M	N/A	1979
Dr. Minang P. Turakhia M.D., M.S.	Chief Medical & Scientific Officer and Executive VP of Product Innovation	749,18k	N/A	1974
Mr. Patrick Michael Murphy J.D.	Chief Business & Legal Officer	766,93k	N/A	1979
Mr. Chad M. Patterson	Chief Commercial Officer	836,55k	N/A	1982
Mr. Mervin Smith	Executive Vice President of Business Operations	N/A	N/A	1975
Mr. Marc Rosenbaum	Senior VP of Finance & Chief Accounting Officer	N/A	N/A	1972
Mr. Daniel G. Wilson	Executive VP of Corporate Development & Investor Relations	670,09k	N/A	1982
Ms. Sumi Shrishrimal	Executive VP & Chief Risk Officer	N/A	N/A	1979
Ms. Stephanie Zhadkevich	Director of Investor Relations	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.

Gobierno corporativo

El ISS Governance QualityScore de iRhythm Technologies, Inc., a día 1 de septiembre de 2024, es 9. Las puntuaciones base son Auditoría: 9; Tablero: 5; Derechos de los accionistas: 6; Compensación: 10.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.